Skip to main content
x

Delivering innovative approaches

Neurelis drug delivery technology

Since 2007, Neurelis has been dedicated to providing solutions for unmet medical needs. To this end, we have acquired delivery technologies to enhance drug development and performance. We leverage these technologies in our own products as well as in products being developed by our partners.

Neurelis Technology Portfolio

Intravail®

The science of Intravail enables the non-invasive delivery of a broad range of protein, peptide, and non-peptide drugs, including small molecules. Intravail can be utilized via the oral, buccal, dermal, and intranasal routes of administration, providing several advantages:

  • Increased bioavailability

    Addressing sub-optimal drug absorption

  • Application to wide range of molecules

    Small molecules, therapeutic proteins, peptides, non-peptide macromolecules (up to ~ 30KDa)

  • Safety

    Odorless, tasteless, non-toxic, non-mutagenic, and non-irritating

  • Solubility in water and oils

    Compatible with routine liquid formulation and dispensing processes for ease of scale-up and production

CONTACT US ABOUT LICENSING INTRAVAIL

Protek®

ProTek protein technology aids in stabilization that prevents the clustering of proteins and peptides, thus reducing immunogenicity. ProTek allows the creation of easily manufacturable, homogeneous, stable, aqueous or lyophilized dosage forms for therapeutics that maintain the structural integrity and physiological activity of many protein and peptide drugs. Formulations are applicable to injectable, intranasal, and other dosage forms.

CONTACT US ABOUT LICENSING PROTEK

Hydrogel®

Hydrogel is an absorption-enhancing water-based gel used for transdermal and transmucosal drug delivery applications. Hydrogel serves simultaneously as a delivery vehicle and absorption enhancer. In dermal applications, Hydrogel leaves the skin feeling soft without residue. The thixotropic nature of Hydrogel prevents dripping and running when dispensing, which allows the gel to self-stabilize as soon as it is applied to the affected area.

CONTACT US ABOUT LICENSING HYDROGEL

Supporting Publications

Download the supporting publications below for more information on the Neurelis Technology Portfolio

Bioequivalence of biotherapeutics – looking beyond bioavailability and pharmacodynamics DOWNLOAD PDF

Circumventing polysorbate induced unwanted immunogenicity and anaphylaxis DOWNLOAD PDF

Reducing or eliminating polysorbate induced anaphylaxis and unwanted immunogenicity in biotherapeutics DOWNLOAD PDF

Polysorbates, biotherapeutics, and anaphylaxis DOWNLOAD PDF

Alkyl mono- and diglucosides: highly effective, nonionic surfactant replacements for polysorbates in biotherapeutics—a review DOWNLOAD PDF

Absorption enhancing excipients in nasal drug delivery DOWNLOAD PDF

Biosimilars, oxidative damage, and unwanted immunogenicity DOWNLOAD PDF

Highly bioavailable nasal calcitonin – potential for expanded use in analgesia DOWNLOAD PDF

Novel excipients prevent aggregation in manufacturing and formulation of protein and peptide therapeutics DOWNLOAD PDF

LICENSE OUR TECHNOLOGY AND MAKE YOUR VISION A REALITY

PARTNER WITH US
SEE OUR PARTNERS